Scheppach W, Richter F, Joeres R, Richter E, Kasper H
Department of Medicine, Würzburg University, Federal Republic of Germany.
Am J Gastroenterol. 1988 Aug;83(8):850-3.
In 15 patients with cirrhosis of the liver and 10 control subjects, 7.5 mmol sodium propionate and 7.5 mmol sodium acetate were instilled endoscopically into the duodenum. Venous concentrations of propionate and acetate were measured for 90 min after administration of the enteral dose by gas-liquid chromatography. In patients with liver cirrhosis, propionate rose from a basal value of 6.1 +/- 4.7 (SD) microM to a peak concentration of 50.1 +/- 25.6 microM, whereas, in controls, it rose only from 1.4 +/- 1.6 to 10.3 +/- 7.6 microM. The oral propionate clearance was significantly lower in patients with cirrhosis (4.51 +/- 1.63 L/min) than in controls (118.47 +/- 154.79 L/min). Acetate went up from 39.5 +/- 16.3 to 134.1 +/- 62.7 microM in patients with cirrhosis and from 60.9 +/- 19.0 to 102.0 +/- 44.0 microM in controls. The oral acetate clearance was lower in patients with liver cirrhosis (2.80 +/- 2.17 L/min) than in control persons (10.86 +2- 5.72 L/min). The differences between the groups were more striking for propionate than for acetate values. It is concluded that the systemic availability of propionate and acetate is higher in patients with liver cirrhosis than in controls. This may be due to portosystemic shunting and/or diminished hepatic and extrahepatic extraction of the acids.
对15例肝硬化患者和10名对照者经内镜将7.5 mmol丙酸钠和7.5 mmol乙酸钠注入十二指肠。经气液色谱法测定肠内给药后90分钟内丙酸盐和乙酸盐的静脉浓度。肝硬化患者中,丙酸盐从基础值6.1±4.7(标准差)μM升至峰值浓度50.1±25.6μM,而在对照组中,仅从1.4±1.6μM升至10.3±7.6μM。肝硬化患者口服丙酸盐清除率(4.51±1.63 L/min)显著低于对照组(118.47±154.79 L/min)。肝硬化患者中乙酸盐从39.5±16.3μM升至134.1±62.7μM,对照组中从60.9±19.0μM升至102.0±44.0μM。肝硬化患者口服乙酸盐清除率(2.80±2.17 L/min)低于对照组(10.86±5.72 L/min)。丙酸盐组间差异比乙酸盐值更显著。结论是,肝硬化患者中丙酸盐和乙酸盐的全身利用率高于对照组。这可能是由于门体分流和/或肝脏及肝外对这些酸的摄取减少。